Glycolytic inhibition: A novel approach toward controlling neuronal excitability and seizures

Research output: Contribution to journalArticle

Abstract

Conventional antiseizure medications reduce neuronal excitability through effects on ion channels or synaptic function. In recent years, it has become clear that metabolic factors also play a crucial role in the modulation of neuronal excitability. Indeed, metabolic regulation of neuronal excitability is pivotal in seizure pathogenesis and control. The clinical effectiveness of a variety of metabolism-based diets, especially for children with medication-refractory epilepsy, underscores the applicability of metabolic approaches to the control of seizures and epilepsy. Such diets include the ketogenic diet, the modified Atkins diet, and the low-glycemic index treatment (among others). A promising avenue to alter cellular metabolism, and hence excitability, is by partial inhibition of glycolysis, which has been shown to reduce seizure susceptibility in a variety of animal models as well as in cellular systems in vitro. One such glycolytic inhibitor, 2-deoxy-d-glucose (2DG), increases seizure threshold in vivo and reduces interictal and ictal epileptiform discharges in hippocampal slices. Here, we review the role of glucose metabolism and glycolysis on neuronal excitability, with specific reference to 2DG, and discuss the potential use of 2DG and similar agents in the clinical arena for seizure management.

Original languageEnglish (US)
Pages (from-to)191-197
Number of pages7
JournalEpilepsia Open
Volume3
DOIs
StatePublished - Dec 1 2018

Fingerprint

Seizures
Glucose
Glycolysis
Epilepsy
Ketogenic Diet
Carbohydrate-Restricted Diet
Diet
Glycemic Index
Ion Channels
Animal Models
Stroke
Therapeutics

Keywords

  • 2-Deoxy-d-glucose
  • Epilepsy
  • Glycolysis
  • Ketogenic diet
  • Metabolic therapy

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Glycolytic inhibition : A novel approach toward controlling neuronal excitability and seizures. / Shao, Lirong; Rho, Jong M.; Stafstrom, Carl.

In: Epilepsia Open, Vol. 3, 01.12.2018, p. 191-197.

Research output: Contribution to journalArticle

@article{4aaa869d47e340f5b7f68eccc308b924,
title = "Glycolytic inhibition: A novel approach toward controlling neuronal excitability and seizures",
abstract = "Conventional antiseizure medications reduce neuronal excitability through effects on ion channels or synaptic function. In recent years, it has become clear that metabolic factors also play a crucial role in the modulation of neuronal excitability. Indeed, metabolic regulation of neuronal excitability is pivotal in seizure pathogenesis and control. The clinical effectiveness of a variety of metabolism-based diets, especially for children with medication-refractory epilepsy, underscores the applicability of metabolic approaches to the control of seizures and epilepsy. Such diets include the ketogenic diet, the modified Atkins diet, and the low-glycemic index treatment (among others). A promising avenue to alter cellular metabolism, and hence excitability, is by partial inhibition of glycolysis, which has been shown to reduce seizure susceptibility in a variety of animal models as well as in cellular systems in vitro. One such glycolytic inhibitor, 2-deoxy-d-glucose (2DG), increases seizure threshold in vivo and reduces interictal and ictal epileptiform discharges in hippocampal slices. Here, we review the role of glucose metabolism and glycolysis on neuronal excitability, with specific reference to 2DG, and discuss the potential use of 2DG and similar agents in the clinical arena for seizure management.",
keywords = "2-Deoxy-d-glucose, Epilepsy, Glycolysis, Ketogenic diet, Metabolic therapy",
author = "Lirong Shao and Rho, {Jong M.} and Carl Stafstrom",
year = "2018",
month = "12",
day = "1",
doi = "10.1002/epi4.12251",
language = "English (US)",
volume = "3",
pages = "191--197",
journal = "Epilepsia Open",
issn = "2470-9239",
publisher = "Wiley-Blackwell Publishing Ltd",

}

TY - JOUR

T1 - Glycolytic inhibition

T2 - A novel approach toward controlling neuronal excitability and seizures

AU - Shao, Lirong

AU - Rho, Jong M.

AU - Stafstrom, Carl

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Conventional antiseizure medications reduce neuronal excitability through effects on ion channels or synaptic function. In recent years, it has become clear that metabolic factors also play a crucial role in the modulation of neuronal excitability. Indeed, metabolic regulation of neuronal excitability is pivotal in seizure pathogenesis and control. The clinical effectiveness of a variety of metabolism-based diets, especially for children with medication-refractory epilepsy, underscores the applicability of metabolic approaches to the control of seizures and epilepsy. Such diets include the ketogenic diet, the modified Atkins diet, and the low-glycemic index treatment (among others). A promising avenue to alter cellular metabolism, and hence excitability, is by partial inhibition of glycolysis, which has been shown to reduce seizure susceptibility in a variety of animal models as well as in cellular systems in vitro. One such glycolytic inhibitor, 2-deoxy-d-glucose (2DG), increases seizure threshold in vivo and reduces interictal and ictal epileptiform discharges in hippocampal slices. Here, we review the role of glucose metabolism and glycolysis on neuronal excitability, with specific reference to 2DG, and discuss the potential use of 2DG and similar agents in the clinical arena for seizure management.

AB - Conventional antiseizure medications reduce neuronal excitability through effects on ion channels or synaptic function. In recent years, it has become clear that metabolic factors also play a crucial role in the modulation of neuronal excitability. Indeed, metabolic regulation of neuronal excitability is pivotal in seizure pathogenesis and control. The clinical effectiveness of a variety of metabolism-based diets, especially for children with medication-refractory epilepsy, underscores the applicability of metabolic approaches to the control of seizures and epilepsy. Such diets include the ketogenic diet, the modified Atkins diet, and the low-glycemic index treatment (among others). A promising avenue to alter cellular metabolism, and hence excitability, is by partial inhibition of glycolysis, which has been shown to reduce seizure susceptibility in a variety of animal models as well as in cellular systems in vitro. One such glycolytic inhibitor, 2-deoxy-d-glucose (2DG), increases seizure threshold in vivo and reduces interictal and ictal epileptiform discharges in hippocampal slices. Here, we review the role of glucose metabolism and glycolysis on neuronal excitability, with specific reference to 2DG, and discuss the potential use of 2DG and similar agents in the clinical arena for seizure management.

KW - 2-Deoxy-d-glucose

KW - Epilepsy

KW - Glycolysis

KW - Ketogenic diet

KW - Metabolic therapy

UR - http://www.scopus.com/inward/record.url?scp=85063924187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063924187&partnerID=8YFLogxK

U2 - 10.1002/epi4.12251

DO - 10.1002/epi4.12251

M3 - Article

C2 - 30564778

AN - SCOPUS:85063924187

VL - 3

SP - 191

EP - 197

JO - Epilepsia Open

JF - Epilepsia Open

SN - 2470-9239

ER -